Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Foghorn Therapeutics Inc. FHTX

Healthcare Biotechnology
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company engaged in developing medicines that modulate gene expression through selectively targeting the chromatin regulatory system for therapeutic intervention in oncology. Its Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within the system. The Company’s Traffic Control platform discovers and develops drugs in oncology and other therapeutic areas, including virology, autoimmune disease and neurology. The Company is developing FHD-286, a selective, allosteric ATPase inhibitor and which is evaluating two separate Phase I studies in metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia, and myelodysplastic syndrome. It is also developing FHD-909 a highly potent, allosteric and orally available small molecule.


NDAQ:FHTX - Post by User

Foghorn Therapeutics Inc.
<< Previous
 Bullboard Posts
User Avatar Image
(9)
•••
Post by MikeTesteron Aug 02, 2024 2:03pm
21 Views
Post# 36161477

Foghorn Therapeutics Inc. (NASDAQ:FHTX): Pioneering a New Cl

Foghorn Therapeutics Inc. (NASDAQ:FHTX): Pioneering a New Clhttps://beyondspx.com/2024/07/31/foghorn-therapeutics-inc-nasdaqfhtx-pioneering-a-new-class-of-precision-medicines-targeting-the-chromatin-regulatory-system/
<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities